Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11437419 | 0.84 | AOC3 (0.56) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL15195453 | 0.84 | AOC3 (0.59) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL2204954 | 0.84 | AOC3 (0.43) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL11080756 | 0.83 | PBRM1 (0.50) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL2209006 | 0.83 | AOC3 (0.42) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL171610 | 0.82 | PBRM1 (0.49) | AOC3L3MBTL1PBRM1CASR | |
| SCHEMBL16084811 | 0.81 | ALOX5 (0.46) | PPARGTSHRMAPK1 | |
| SCHEMBL7856698 | 0.81 | PBRM1 (0.55) | AOC3L3MBTL1PBRM1CASR | |
| SCHEMBL9236006 | 0.81 | AOC3 (0.50) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL18602502 | 0.81 | AOC3 (0.48) | AOC3L3MBTL1PBRM1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253489-B2 | Visual cycle modulators | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200060996-A1 | VISUAL CYCLE MODULATORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060996-A1 | VISUAL CYCLE MODULATORS | ALDH1A2, UACA, NR2E3 | AOC3 4210/4885L3MBTL1 4629/4885CHRM2 691/4885 |
| US-11253489-B2 | Visual cycle modulators | ALDH1A2, UACA, NR2E3 | AOC3 4210/4885L3MBTL1 4629/4885CHRM2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.